Send us a Message



Submit Data |  Help |  Video Tutorials |  News |  Publications |  Download |  REST API |  Citing RGD |  Contact   

CHEBI ONTOLOGY - ANNOTATIONS

The Chemical Entities of Biological Interest (ChEBI) ontology is downloaded weekly from EMBL-EBI at http://www.ebi.ac.uk/chebi/. The data is made available under the Creative Commons License (CC BY 3.0, http://creativecommons.org/licenses/by/3.0/). For more information see: Degtyarenko et al. (2008) ChEBI: a database and ontology for chemical entities of biological interest. Nucleic Acids Res. 36, D344–D350.

Term:VX nerve agent
go back to main search page
Accession:CHEBI:136185 term browser browse the term
Definition:A organic thiophosphate that is the ethyl ester of S-{2-[di(propan-2-yl)amino]ethyl} O hydrogen methylphosphonothioate. A toxic nerve agent used in chemical warfare.
Synonyms:exact_synonym: S-{2-[di(propan-2-yl)amino]ethyl} O-ethyl methylphosphonothioate
 related_synonym: Ethyl S-2-diisopropylaminoethyl methylphosphonothiolate;   Ethyl-S-diisopropylaminoethyl methylthiophosphonate;   Formula=C11H26NO2PS;   InChI=1S/C11H26NO2PS/c1-7-14-15(6,13)16-9-8-12(10(2)3)11(4)5/h10-11H,7-9H2,1-6H3;   InChIKey=JJIUCEJQJXNMHV-UHFFFAOYSA-N;   O-Ethyl S-(2-diisopropylaminoethyl) methylphosphonothioate;   O-ethyl-S-[2-(N,N-diisopropylamino)ethyl] ester;   S-(2-Diisopropylaminoethyl) O-ethyl methyl phosphonothiolate;   SMILES=CC(N(CCSP(OCC)(=O)C)C(C)C)C;   VX
 xref: CAS:50782-69-9;   Chemspider:36386
 xref_mesh: MESH:C009680
 xref: PMID:20947456;   PMID:21862421;   PMID:21905719;   PMID:22042427;   PMID:23083335;   PMID:23126561;   PMID:23402290;   PMID:23872337;   PMID:24517492;   PMID:24633585;   PMID:24766293;   PMID:24854058;   PMID:24972874;   PMID:26327407;   PMID:26561750;   PMID:27113675;   PMID:27594690;   PMID:27627873;   PMID:28098192;   PMID:28179194;   PMID:28267914;   Reaxys:1949015;   Wikipedia:VX_(nerve_agent)


show annotations for term's descendants           Sort by:
 
VX nerve agent term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Ache acetylcholinesterase decreases activity
multiple interactions
increases metabolic processing
decreases response to substance
ISO
EXP
VX analog results in decreased activity of ACHE protein; VX results in decreased activity of ACHE protein
4-amino-2-((diethylamino)methyl)phenol analog inhibits the reaction [VX results in decreased activity of ACHE protein]; ACHE protein mutant form promotes the reaction [asoxime chloride results in decreased susceptibility to VX]; asoxime chloride affects the reaction [VX results in decreased activity of ACHE protein]; asoxime chloride inhibits the reaction [VX results in decreased activity of ACHE protein]; benzohydroxamic acid analog inhibits the reaction [VX results in decreased activity of ACHE protein]; Cholinesterase Reactivators inhibits the reaction [VX binds to and results in decreased activity of ACHE protein]; Cholinesterase Reactivators inhibits the reaction [VX results in decreased activity of ACHE protein]; diacetylmonoxime inhibits the reaction [VX binds to and results in decreased activity of ACHE protein]; HLo 7 affects the reaction [VX results in decreased activity of ACHE protein]; isonitrosoacetone inhibits the reaction [VX binds to and results in decreased activity of ACHE protein]; isonitrosoacetone inhibits the reaction [VX results in decreased activity of ACHE protein]; N,N'-monomethylenebis(pyridiniumaldoxime) inhibits the reaction [VX binds to and results in decreased activity of ACHE protein]; N,N'-monomethylenebis(pyridiniumaldoxime) inhibits the reaction [VX results in decreased activity of ACHE protein]; Obidoxime Chloride inhibits the reaction [VX results in decreased activity of ACHE protein]; Oximes analog inhibits the reaction [VX results in decreased activity of ACHE protein]; Pralidoxime Compounds analog inhibits the reaction [VX results in decreased activity of ACHE protein]; pralidoxime inhibits the reaction [VX analog results in decreased activity of ACHE protein]; pralidoxime inhibits the reaction [VX binds to and results in decreased activity of ACHE protein]; pralidoxime inhibits the reaction [VX results in decreased activity of ACHE protein]; pralidoxime metabolite inhibits the reaction [VX results in decreased activity of ACHE protein]; pyridine-4-aldoxime analog inhibits the reaction [VX results in decreased activity of ACHE protein]; Pyridinium Compounds inhibits the reaction [VX results in decreased activity of ACHE protein]; pyridoxaloxime analog inhibits the reaction [VX results in decreased activity of ACHE protein]; RS194B analog inhibits the reaction [VX binds to and results in decreased activity of ACHE protein]; RS194B inhibits the reaction [VX binds to and results in decreased activity of ACHE protein]; RS41A inhibits the reaction [VX binds to and results in decreased activity of ACHE protein]; VX binds to and results in decreased activity of ACHE protein
VX results in increased metabolism of ACHE protein
ACHE results in decreased susceptibility to VX
1-(4-carbamoylpyridinium)-4-(4-hydroxyiminomethylpyridinium)but-2-ene inhibits the reaction [VX results in decreased activity of ACHE protein]; [asoxime chloride co-treated with 1-(4-carbamoylpyridinium)-4-(4-hydroxyiminomethylpyridinium)but-2-ene] inhibits the reaction [VX results in decreased activity of ACHE protein]; [asoxime chloride co-treated with Trimedoxime] inhibits the reaction [VX results in decreased activity of ACHE protein]; asoxime chloride inhibits the reaction [VX results in decreased activity of ACHE protein]; Trimedoxime inhibits the reaction [VX results in decreased activity of ACHE protein]; VX binds to and results in increased phosphorylation of and results in decreased activity of ACHE protein
1-(4-carbamoylpyridinium)-4-(4-hydroxyiminomethylpyridinium)but-2-ene inhibits the reaction [VX results in decreased activity of ACHE protein]; [asoxime chloride co-treated with 1-(4-carbamoylpyridinium)-4-(4-hydroxyiminomethylpyridinium)but-2-ene] inhibits the reaction [VX results in decreased activity of ACHE protein]; [asoxime chloride co-treated with Trimedoxime] inhibits the reaction [VX results in decreased activity of ACHE protein]; asoxime chloride inhibits the reaction [VX results in decreased activity of ACHE protein]; Cholinesterase Reactivators inhibits the reaction [VX analog results in decreased activity of ACHE protein]; pralidoxime inhibits the reaction [VX analog results in decreased activity of ACHE protein]; Pyridinium Compounds inhibits the reaction [VX analog results in decreased activity of ACHE protein]; Trimedoxime inhibits the reaction [VX analog results in decreased activity of ACHE protein]; Trimedoxime inhibits the reaction [VX results in decreased activity of ACHE protein]
CTD PMID:1609424 PMID:12415428 PMID:14631503 PMID:16167316 PMID:17299830 PMID:17370251 PMID:17402711 PMID:18579126 PMID:18617161 PMID:20412789 PMID:20433814 PMID:20669006 PMID:20888357 PMID:21504785 PMID:21783513 PMID:21930118 PMID:22013137 PMID:22407886 PMID:22975155 PMID:22982773 PMID:23073172 PMID:23111374 PMID:23123249 PMID:25451328 PMID:26070418 PMID:26972668 PMID:27083141 PMID:27129421 PMID:27138243 PMID:27358236 PMID:27693733 PMID:29920286 PMID:30312685 PMID:31863869 PMID:32720192 NCBI chr12:22,472,358...22,477,052
Ensembl chr12:22,472,358...22,478,753
JBrowse link
G Bche butyrylcholinesterase decreases activity
multiple interactions
ISO VX analog results in decreased activity of BCHE protein; VX metabolite results in decreased activity of BCHE protein; VX results in decreased activity of BCHE protein
[BCHE protein co-treated with asoxime chloride co-treated with pro-diazepam co-treated with Atropine] results in decreased susceptibility to VX; asoxime chloride inhibits the reaction [VX results in decreased activity of BCHE protein]; Obidoxime Chloride inhibits the reaction [VX results in decreased activity of BCHE protein]; Oximes analog inhibits the reaction [VX results in decreased activity of BCHE protein]; pralidoxime inhibits the reaction [VX analog results in decreased activity of BCHE protein]; pyridoxaloxime analog inhibits the reaction [VX results in decreased activity of BCHE protein]
CTD PMID:17698511 PMID:18617161 PMID:19428953 PMID:22407886 PMID:22981459 PMID:27358236 PMID:27693733 PMID:29920286 PMID:31863869 NCBI chr 2:171,104,476...171,196,186
Ensembl chr 2:171,100,140...171,196,395
JBrowse link
G Bdnf brain-derived neurotrophic factor increases expression ISO VX results in increased expression of BDNF mRNA; VX results in increased expression of BDNF protein CTD PMID:22240983 NCBI chr 3:100,768,637...100,819,216
Ensembl chr 3:100,768,637...100,819,210
JBrowse link
G Chrm2 cholinergic receptor, muscarinic 2 decreases expression EXP VX results in decreased expression of CHRM2 protein CTD PMID:29127449 NCBI chr 4:64,089,028...64,091,090
Ensembl chr 4:64,088,900...64,091,090
JBrowse link
G Idh2 isocitrate dehydrogenase (NADP(+)) 2 decreases activity EXP VX results in decreased activity of IDH2 protein CTD PMID:28267914 NCBI chr 1:141,874,354...141,893,674
Ensembl chr 1:141,866,283...141,893,705
JBrowse link
G Krt10 keratin 10 affects binding ISO VX binds to KRT10 protein CTD PMID:22521715 NCBI chr10:87,296,445...87,301,307
Ensembl chr10:87,296,451...87,300,736
JBrowse link
G Pepd peptidase D increases hydrolysis ISO PEPD protein results in increased hydrolysis of VX CTD PMID:22120822 NCBI chr 1:90,820,670...91,285,128 JBrowse link
G Pon1 paraoxonase 1 decreases response to substance
increases hydrolysis
ISO PON1 protein mutant form results in decreased susceptibility to VX
PON1 protein mutant form results in increased hydrolysis of VX; PON1 protein results in increased hydrolysis of VX
CTD PMID:20176005 PMID:23159884 NCBI chr 4:30,249,749...30,276,297
Ensembl chr 4:30,249,742...30,276,372
JBrowse link
G Ptgs2 prostaglandin-endoperoxide synthase 2 increases expression
multiple interactions
EXP VX results in increased expression of PTGS2 mRNA; VX results in increased expression of PTGS2 protein
[N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide results in decreased activity of PTGS2 protein] which results in decreased susceptibility to VX
CTD PMID:22306367 NCBI chr13:67,351,230...67,356,920
Ensembl chr13:67,351,087...67,359,335
JBrowse link

Term paths to the root
Path 1
Term Annotations click to browse term
  CHEBI ontology 19771
    role 19716
      biological role 19716
        aetiopathogenetic role 18967
          neurotoxin 17662
            VX nerve agent 9
Path 2
Term Annotations click to browse term
  CHEBI ontology 19771
    subatomic particle 19770
      composite particle 19770
        hadron 19770
          baryon 19770
            nucleon 19770
              atomic nucleus 19770
                atom 19770
                  main group element atom 19658
                    p-block element atom 19658
                      chalcogen 19387
                        oxygen atom 19350
                          oxygen molecular entity 19350
                            hydroxides 19076
                              oxoacid 18275
                                pnictogen oxoacid 10312
                                  phosphorus oxoacid 9234
                                    phosphoric acids 7954
                                      phosphoric acid 7954
                                        phosphoric acid derivative 7634
                                          phosphate 7634
                                            organic phosphate 7633
                                              organic thiophosphate 2895
                                                VX nerve agent 9
paths to the root